Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Axsome Thera (NQ: AXSM )

97.50 -1.18 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 665,735
Open 98.88
Bid (Size) 93.00 (1)
Ask (Size) 100.62 (1)
Prev. Close 98.68
Today's Range 96.67 - 100.61
52wk Range 61.14 - 105.00
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics
Via Benzinga

Performance

YTD
+26.52%
+26.52%
1 Month
+8.20%
+8.20%
3 Month
+10.16%
+10.16%
6 Month
+27.02%
+27.02%
1 Year
+47.15%
+47.15%

More News

Read More
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Via Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Unveiling 14 Analyst Insights On Axsome Therapeutics
Via Benzinga
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts
Via Benzinga
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
From Axsome Therapeutics, Inc.
Via GlobeNewswire
1 Under-the-Radar Biotech Stock to Buy and Hold
Via The Motley Fool
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Participate in Investor Conferences in September
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Axsome Therapeutics Stock Is Sinking Today
Via The Motley Fool
Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth
Via Investor's Business Daily
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Via FinancialNewsMedia
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.